Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025.
The company's management will deliver an on-demand presentation, which will be available through the Presentation & Events section on Aligos' investor relations website. The webcast recording will remain accessible for at least 30 days after the presentation.
Aligos Therapeutics (Nasdaq: ALGS), società biofarmaceutica in fase clinica specializzata in terapie per fegato e malattie virali, ha annunciato la sua partecipazione al 27° H.C. Wainwright Annual Global Investment Conference, in programma dall'8 al 10 settembre 2025.
Il management dell'azienda presenterà un intervento on-demand, disponibile nella sezione Presentation & Events del sito investor relations di Aligos. La registrazione del webcast resterà accessibile per almeno 30 giorni dopo la pubblicazione.
Aligos Therapeutics (Nasdaq: ALGS), una compañía biofarmacéutica en fase clínica especializada en terapias para el hígado y enfermedades virales, anunció su participación en la 27ª Conferencia Anual Global de Inversiones H.C. Wainwright, programada del 8 al 10 de septiembre de 2025.
La dirección de la compañía ofrecerá una presentación on-demand, que estará disponible en la sección Presentation & Events del sitio de relaciones con inversores de Aligos. La grabación del webcast permanecerá accesible durante al menos 30 días tras la presentación.
Aligos Therapeutics (Nasdaq: ALGS), 간 및 바이러스성 질환 치료제에 주력하는 임상 단계 바이오제약회사, 가 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 2025년 9월 8~10일 참가한다고 발표했습니다.
회사 경영진은 온디맨드 발표를 진행하며, 해당 발표는 Aligos 투자자 관계 웹사이트의 Presentation & Events 섹션에서 이용할 수 있습니다. 웹캐스트 녹화는 발표 후 최소 30일간 시청 가능하게 유지됩니다.
Aligos Therapeutics (Nasdaq: ALGS), une société biopharmaceutique en phase clinique spécialisée dans les traitements des maladies du foie et virales, a annoncé sa participation à la 27e conférence annuelle mondiale H.C. Wainwright, prévue du 8 au 10 septembre 2025.
La direction de la société délivrera une présentation à la demande, disponible dans la section Presentation & Events du site relations investisseurs d'Aligos. L'enregistrement du webcast restera accessible pendant au moins 30 jours après la présentation.
Aligos Therapeutics (Nasdaq: ALGS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien für Leber- und Viruskrankheiten spezialisiert hat, gab seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference bekannt, die vom 8. bis 10. September 2025 stattfindet.
Das Management des Unternehmens wird eine On-Demand-Präsentation bereitstellen, die in der Rubrik Presentation & Events auf der Investor-Relations-Website von Aligos verfügbar sein wird. Die Aufzeichnung des Webcasts bleibt mindestens 30 Tage nach der Präsentation abrufbar.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025.
A webcast of the on demand presentation will be accessible by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inzioevoke.com
FAQ
When is Aligos Therapeutics (ALGS) presenting at the H.C. Wainwright Conference 2025?
How can investors access Aligos Therapeutics' (ALGS) H.C. Wainwright conference presentation?
What is Aligos Therapeutics' (ALGS) main business focus?
How long will Aligos Therapeutics' (ALGS) conference presentation be available for viewing?
